Ellipses announces first patient dosed with EP0031, a next generation selective RET inhibitor Phase 1/2 trial opened in the US with first patient treated in November 2022 London, UK, 14th December 2022: Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, today announces the first dosing of [...]
Ellipses Pharma presents preliminary data from the first in human phase-1/2 trial of EP0042, a dual FLT-3 and Aurora kinase inhibitor, at ASH Study investigated treatment of patients with AML and initial findings suggest that EP0042 had acceptable safety and tolerability, with evidence of disease stabilisation London, UK, 12 December 2022: Ellipses Pharma Limited (“Ellipses”), [...]
Ellipses Pharma presents design of newly initiated phase 1/2a trial of vosilasarm (EP0062) at SABCS Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, will present a “Trial in Progress” poster detailing the design of a Phase 1/2 trial of vosilasarm (EP0062) in advanced breast cancer [...]
The Professor Gordon McVie Cancer Research Leaders Fellowship By Dr Rajan Jethwa, CEO, Ellipses Pharma. If only there were more Professor Gordon McVies. I’m sure that’s what most of us were thinking when we gathered last week to honour the late renowned oncologist and founding chair of the Ellipses Scientific Affairs Group. Eminent figures from [...]
Ellipses Pharma to present clinical updates at leading U.S conferences Ellipses Pharma to present clinical updates at leading U.S. breast and blood cancer conferences London, UK, 21 November 2022: Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of new oncology treatments, is delighted to announce that it will be [...]
FDA clearance of IND application for EP0031 Ellipses announces FDA clearance of IND application for EP0031 for patients with advanced RET-altered malignancies A phase 1/2 trial to initiate across a range of patient populations with RET-altered cancers Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments [...]
Exclusive licensing agreement Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours LONDON and SANTIAGO DE COMPOSTELA, Spain, May 25th, 2022: SunRock Biopharma S.L. (“SunRock”), a biopharmaceutical company that is developing a portfolio [...]
Our new Global Head of Drug Development and Chief Medical Officer Ellipses Pharma Announces Appointment of Professor Hendrik-Tobias Arkenau as Global Head of Drug Development and Chief Medical Officer Highly Accomplished Oncologist with Proven Track Record in Leading Innovative Drug Development Ellipses Pharma a global drug development company focused on accelerating the development of new [...]
Meet us digitally at the Bio-Europe Spring conference For more information, send us a mail at enquiries@ellipses.life
Ellipses Announces Growth in Oncology Portfolio ELLIPSES ANNOUNCES GROWTH IN ONCOLOGY PORTFOLIO LONDON, September 16, 2021: Ellipses Pharma, the UK-based global drug development company, has today announced a significant increase in its portfolio of potential treatments for a range of cancers. Ellipses has now acquired and is developing seven high-quality drugs of which two are [...]
